This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.
Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89: 732–742.
Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014; 124: 3135.
Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.
Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.
Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013; 42 (9 Pt 2): e303–e310.
Acknowledgements
The authors thank Nathalie Ross, Science and Medical Writer, funded by Novartis Pharmaceuticals for contributing to the writing and editing of this Correspondence. Novartis had no influence on the content of this document.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Christian Constance has received honorarium and support for clinical trials from Astra, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Dr David Langleben has received honoraria and support for clinical trials from Actelio, Bayer, Eiger Biophamaceuticals, Ikaria, Northern Therapeutics, Novartis and United Therapeutics. He has served on advisory boards for Actelion, Bayer, Ikaria, Northern Therapeutics, Novartis, UCB Celltech and United Therapeutics. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Constance, C., Trudeau, L., Jolicoeur, E. et al. Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 31, 771–772 (2017). https://doi.org/10.1038/leu.2016.336
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.336
This article is cited by
-
Chronic Myeloid Leukemia: What Is the Best Strategy to Start and Monitor Treatment Outside Academic Centers?
Current Oncology Reports (2018)